دورية أكاديمية
Rationale for combined therapies in severe-to-critical COVID-19 patients
| العنوان: | Rationale for combined therapies in severe-to-critical COVID-19 patients |
|---|---|
| المؤلفون: | Gonzaga, Aitor, Andreu, Etelvina, Hernández-Blasco, Luis M., Meseguer, Rut, Al-Akioui-Sanz, Karima, Soria-Juan, Bárbara, Sanjuan-Gimenez, Jose Carlos, Ferreras, Cristina, Tejedo, Juan R., López-Lluch, Guillermo, Goterris, Rosa, Maciá Soler, Loreto, Sempere Ortells, José Miguel, Hmadcha, Abdelkrim, Borobia, Alberto, Vicario, Jose L., Bonora, Ana, Aguilar-Gallardo, Cristobal, Poveda, Jose L., Arbona, Cristina, Alenda, Cristina, Tarín, Fabian, Marco, Francisco M., Merino, Esperanza, Jaime, Francisco, Ferreres, José, Figueira, Juan Carlos, Cañada-Illana, Carlos, Querol, Sergio, Guerreiro, Manuel, Eguizabal, Cristina, Martín-Quirós, Alejandro, Robles-Marhuenda, Ángel, Pérez-Martínez, Antonio, Solano, Carlos, Soria, Bernat |
| المساهمون: | Universidad de Alicante. Departamento de Enfermería, Universidad de Alicante. Departamento de Biotecnología, Gestión de Servicios de Enfermería (GESE), Grupo de Inmunología, Biología Celular y del Desarrollo |
| بيانات النشر: | Frontiers Media |
| سنة النشر: | 2023 |
| المجموعة: | RUA - Repositorio Institucional de la Universidad de Alicante |
| مصطلحات موضوعية: | COVID-19, Cytokine storm, Immunomodulation, Mesenchymal stromal cells, SARS-CoV-2, Advanced therapies |
| الوصف: | An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19’s pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients. ; This research was funded by the financial support to BS from: Institute of Health Carlos III (Co-funded by Fondos FEDER), Project ICI21/00016 and Agencia Valenciana de Innovacion Projects AVI-GVA COVID-19-68 and GVA-COVI19/2021/047 and Project JDRF 2-SRA-2019-837. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1664-3224 |
| العلاقة: | https://doi.org/10.3389/fimmu.2023.1232472Test; Gonzaga A, Andreu E, Hernández-Blasco LM, Meseguer R, Al-Akioui-Sanz K, Soria-Juan B, Sanjuan-Gimenez JC, Ferreras C, Tejedo JR, Lopez-Lluch G, Goterris R, Maciá L, Sempere-Ortells JM, Hmadcha A, Borobia A, Vicario JL, Bonora A, Aguilar-Gallardo C, Poveda JL, Arbona C, Alenda C, Tarín F, Marco FM, Merino E, Jaime F, Ferreres J, Figueira JC, Cañada-Illana C, Querol S, Guerreiro M, Eguizabal C, Martín-Quirós A, Robles-Marhuenda Á, Pérez-Martínez A, Solano C and Soria B (2023) Rationale for combined therapies in severe-to-critical COVID-19 patients. Front. Immunol. 14:1232472. doi:10.3389/fimmu.2023.1232472; http://hdl.handle.net/10045/137107Test |
| DOI: | 10.3389/fimmu.2023.1232472 |
| الإتاحة: | https://doi.org/10.3389/fimmu.2023.1232472Test http://hdl.handle.net/10045/137107Test |
| حقوق: | © 2023 Gonzaga, Andreu, Hernández-Blasco, Meseguer, Al-Akioui-Sanz, Soria-Juan, Sanjuan-Gimenez, Ferreras, Tejedo, Lopez-Lluch, Goterris, Maciá, Sempere-Ortells, Hmadcha, Borobia, Vicario, Bonora, Aguilar-Gallardo, Poveda, Arbona, Alenda, Tarín, Marco, Merino, Jaime, Ferreres, Figueira, Cañada-Illana, Querol, Guerreiro, Eguizabal, Martín-Quirós, Robles-Marhuenda, Pérez-Martínez, Solano and Soria. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.CE43731A |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 16643224 |
|---|---|
| DOI: | 10.3389/fimmu.2023.1232472 |